Hereditary Cancer Testing

Cancer Can Be Scary, but You’re Not Powerless against the Disease; GreyStone Is Leading the Charge in the Battle against Cancer

Cancer is an unfortunately common disease, so it’s no surprise cancers often run in families. In fact, approximately 1 in 3 people in the United States will develop cancer during their lifetime. Genetic testing can help providers in ensuring the early detection, diagnosis, and intervention of potentially life-threatening cancers.

Request Test

Name

Email

Phone

Individual Test Inquiries

Message

Finding out Early Whether a Patient Is Prone to a Cancer Could Save a Life.

Advances in genetic diagnostics are improving our understanding of cancer and the nature of its genetic origins. For certain individuals, there is a clear genetic susceptibility or inherited risk for cancer. These individuals and their families may be predisposed to conditions like Lynch Syndrome, or there may be a family genetic history of BRCA1 mutations, BRCA2 mutations, or Li-Fraumeni Syndrome. People from such families can undertake genetic testing to help clarify their risk and determine the cancers for which they’re at increased risk.

Through cutting-edge genetic testing, we can help you determine a patient’s risk factors based on their DNA, so you can mitigate or even eliminate future consequences by taking steps now.

Hereditary Cancer Testing Might Be Right for:

• Individuals with a personal history of cancer.

• Individuals who are concerned about whether their family history puts them at risk for cancer.

It is not uncommon for providers to witness a recurring pattern of cancer across two to three generations, with multiple individuals diagnosed with the same type of cancer.

Knowledge of an increased genetic risk for cancer empowers healthcare providers to develop a precision-based, personalized plan that can detect or even prevent cancer at earlier, more treatable stages. Cancer can be scary, but you’re not alone. GreyStone can help patients and providers understand and mitigate risks for cancer through precision-based genetic testing.